



CODEN [USA]: IAJPBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

<http://doi.org/10.5281/zenodo.2658671>

Available online at: <http://www.iajps.com>

Review Article

REVIEW THE ANNOTATION OF C1236T MONO-NUCLEOTIDE POLYMORPHISM OF ABCB1 GENE ALONG WITH NON-RECEPTIVENESS TOWARDS ANTIEMETIC HANDLING IN VICTIMS BEFORE SURGERY

¹Dr. Tehreem Tariq, ²Dr. Ujala Ihsan, ³Dr Usman Jabir Sukhera

¹Incharge Health Officer, PHFMC Faisalabad, ²Ittefaq Hospital Lahore, ³Medical Officer, BHU Waindla Jageer.

Article Received: March 2019

Accepted: April 2019

Published: May 2019

Abstract:

Objective: Purpose is to review the annotation of C1236T mono-nucleotide polymorphism of ABCB1 gene along with non-receptiveness towards antiemetic handling in victims before surgery.

Methods: Respective medical test was held at Sir Ganga Ram Hospital in Lahore during 2017-18, consisted of victims suffering laparoscopic cholecystectomy. All the victims were provided with dosage of 0.1 mg/kg ondansetron intravenously about half an hour prior to the termination of operation and illustrations for Deoxyribonucleic acid were performed. The regularities of genetic material for mono nucleotide polymorphism were evaluated through the use of PCR along with RFLP.

Results: Among a total of 426 victims, 201(47%) showed resistance against nausea or vomiting, while 225(52.8%) were affected by the disease. Evidence of nausea and vomiting after 2 hours from surgery were rare in victims having relation with 1236TT as compared to 1236C(probability <0.001). Victims of CC inheritance showed huge evidence as compared to others i.e. p < 0.001.

Conclusion: To expect reaction towards ondansetron Polymorphism of ABCB1 gene plays an important role.

Keywords: ATP-binding cassette subfamily B member 1 (ABCB1), Single nucleotide polymorphism, Genotyping, Ondansetron, P-glycoprotein.

Corresponding author:

Dr. Tehreem Tariq,

Incharge Health Officer, PHFMC Faisalabad.

QR code



Please cite this article in press Tehreem Tariq et al., *Review the Annotation of C1236t Mono-Nucleotide Polymorphism of Abcb1 Gene Along With Non-Receptiveness towards Antiemetic Handling in Victims before Surgery.*, Indo Am. J. P. Sci, 2019; 06(05).

INTRODUCTION:

A serious issue of nausea and vomiting after surgery was reported during antiemetic treatment [1]. It donates the pain from which victims are suffering. An oppositional serotonin receptor towards ondansetron is frequently utilized medicine against nausea and vomiting (PONV) which is very useful and secure [2]. Despite of its utilization some cases of about 35% victims reported PONV which showed that it is not effective for all individuals. The motive behind this deviation is still mysterious. Several aspects contributed to this nausea and vomiting, however, the fact of inherited circumstances is considered as the key aspect [3]. Ondansetron is documented through adenosine 5'-triphosphate-binding cassette belonging to subfamily B participant 1(ABCB1) that carries drug towards blood brain barricade that governs the proportion of drug in central nervous system (CNS).

ABCB1 is the genotype that shows huge polymorphism due to which appearance and purpose of P-glycoprotein (P-gp) is altered that stimulates the drug temperament in the central nervous system altering usefulness and dealing results. Huge research has been conducted in nucleotide locations G2677T at exon 21 and C3435T at exon 27, despite of which C1236T got less consideration at exon 24 [4]. Moreover, connotational polymorphism in the ABCB1 gene and clinical comebacks were inspected at various ethnic groups [5-8] but the records for our population were lacking. Evaluation of the incidence of structurally significant mono-nucleotide polymorphism for the inhabitants is of huge concern as it is really difficult for someone to decode the research of pharmacogenetic research in a population to other. The research conducted by various clinical staff were not as accurate for huge emetogenic operations after surgery. These type of research surveys on pharmacogenetics of anesthesia are scarce. Further expertise is required to decode the outcomes of pharmacogenetic surveys into anesthesia. A strategy was built to evaluate the outcome of C1236T polymorphism with respect to cancer victims on therapy results of prophylactic ondansetron in victims after surgery suffering laparoscopic cholecystectomy having primary anesthesia.

It was assumed that ABCB1 polymorphism plays a vital role in the evaluation of reaction of victims after surgery towards ondansetron and polymorphism in gene transfer contribute a lot in interindividual deviation.

PATIENTS AND METHODS:

During 2017-18, a respective clinical survey was held which consists of victims suffering through elective laparoscopic cholecystectomy. When permission was granted from Ethical Committee of Centre for Research in Experimental and Applied Medicine (CREAM), Clinical record was gathered, and sampling was performed at Sir Ganga Ram Hospital, Lahore. Inscribed conversant agreement was derived from all the subjects of older age despite of the categorization of male and female casually chosen from non-probability successive sampling relating to various areas of Pakistan in order to get participation from all regions. Victims of 18-65 years belonging to American Society of Anesthesiologists(ASA) bodily state of I or II planned to suffer elective laparoscopic cholecystectomy were elected. Victims with some previous records of hypersensitivity to 5-HT₃ receptor against it, hepatic or any renal disease or those which utilized antiemetics in 24 hours prior to survey were not included. Complete evaluation of every subject having exhaustive medical record was performed comprising of the record of smoking, motion sickness and any previous record of PONV.

Vitals of victims, consisting of electrocardiography, non-invasive blood pressure (BP) and pulse oximetry, were observed regularly if the victim got into the surgery room. Training was held with 4-5 mg/kg thiopental, and endotracheal intubation was performed with 0.6 mg/kg rocuronium. Also, 1.5-2.0 vol% sevoflurane and nalbuphine 0.1 mg/kg-1 was utilized for regulation of anesthesia. Through the technique a bispectral index score (BIS) observer was utilized regularly and deepness of anesthesia was regulated among 50-60. All the victims were treated with 4mg(0.1 mg/kg) ondansetron through veins (IV) half an hour prior to operative completion. Overall dosage of nalbuphine utilization during anesthesia was recorded. After entrance of post anesthesia care unit, the suffering data was noted. In duration after surgery, all victims were monitored for indications of nausea and vomiting. PONV during initial 2 hours and at 2-24 hours was observed. Victims showing any symptoms of nausea and vomiting were assigned to the category of non-responders. These victims were regarded as treatment abortive and were treated with salvage antiemetic. Victims were assigned to the responder's category on the basis of no clear symptoms of nausea and vomiting after surgery. The blood samples of 5ml were obtained from each victim.

Average biological procedures of deoxyribonucleic acid (DNA) withdrawal were utilized to separate the genomic DNA from entire blood.[10] PCR-RFLP was utilized for genotyping of C1236T. DNA

augmentation was performed through utilization of sense:5'GCCACaGTCTGCCCACTC3' and anti-sense: 5'CCCATaTCGAAAAGAAATTAAG3 primers for the area sheltering the C1236T SNP. The procedure of PCR was performed in the total concentration of 20µl having 10X PCR buffer lacking MG2+, 25 Mm MGCL2, 2 mMdNTPs, 5U Taq polymerase, 10 µM forward and reverse primers and 40 mg DNA of genomic origin. Products of Polymerase Chain Reaction were imperiled to assimilation through the aid of restriction enzyme (Hae III). After assimilation the homozygous population for primary allele have 3 fragments of 272bp, 63bp and 35bp. This heterozygous population is composed of primary and secondary allele leading to 4 fragments of 272bp, 98bp, 63bp and 35bp. The secondary allele of homozygous population develop 2 fragments of 272bp and 98bp fragments. Evaluation of the record was performed through utilization of SPSS 22. For regulation of the Single Nucleotide Polymorphism variation from Hardy Weinberg equilibrium through Fisher's exact test was performed. Regulation variations in genotype and occurrence of PONV were associated with chi-square test.

Utilization of odds ratios (ORs) and 95% confidence interval for correlation of ABCB1 genotypic deviations with the existence of PONV. P<0.05 was regarded as substantial.

RESULTS:

Out of 426 victims, 70(16.4%) showed CC genotype, 188(44%) with CT while 168(39.5%) with TT(Table 1). Substantial variation was lacking in features and clinical explanation depending on the genotypes (p>0.05). From C1236T variants, occurrence of PONV within 2 hours to operation was substantially less in victims having 1236TT genotype as compared to 1236 genotypes (TT vs CC+CT; p<0.001). Existence of PONV was substantially huge in victims having CC genotype within 2 hours as compared to 1236 genotype (CC vs CT+TT; p<0.001)(Table 2). Reaction towards ondansetron depending on PONV showed no variation among genotypes during 2-24 hours after operation. Reaction of victims suffering from nausea and vomiting was minimized showing a rate of 62(14.5%) victims.

Table-1: Patient characteristics and clinical details according to C1236T genotype.

Variables	CC (n=70)	Genotype CT (n= 188)	TT (n=168)
Sex: M/F	27/43	98/90	64/104
Age (years)	42.84±10.43	41.98±8.65	42.82±8.29
History of Smoking	7	30	19
History of PONV	8	15	14
History of motion sickness	5	22	11
Duration of Surgery	76.93±11.12	77.23±12.06	76.76±9.96
Nalbuphine doses in operating room (mg/kg)	6.66±0.78	7.10±0.31	6.23±0.42





Table-2: The effects of C1236T ABCB1 polymorphism on the antiemetic efficacy of ondansetron at 2 hours and at 2-24 hours.

Genotypes	First 2 hours		2-24 hours	
	Responders	Non-Responders	Responders	Non-Responders
CC	23(32.9%)	47(67.1%)	59(84.3%)	11 (15.7%)
CT	74(39.4%)	114 (60.6%)	156(83%)	32 (17%)
TT	104 (61.9%)	64 (38.1%)	149(88.7%)	19 (11.3%)
	OR (95% CI), p-values			
CC+CT vs TT	2.6972(1.08-4.02) < 0.001*		1.5684(0.87-2.79) 0.125	
CC vs CT + TT	0.4894(0.28-0.84) <0.001*		1.3344(0.65-2.72)0.763	

CI indicates confidence interval; OR, odds ratio; *p<0.05

ABCB1: Adenosine 5'-triphosphate binding cassette subfamily B member 1.



DISCUSSION:

Exchange of P-gp is determined by a huge polymorphic gene ABCB1. Single Nucleotide Polymorphism has little research done in case of healthy individuals, moreover, clinical position is the variation at location 1236 in exon 12(C1236T). This type of polymorphism alters the appearance and working of P-gp influencing the accuracy of medicine acting as substrates of P-gp. [10, 11] It is very obvious that polymorphism of ABCB1 evaluation could be performed in person through therapeutic strategy. The results are un-satisfying and opposing the hushed C1236T polymorphism among deviated individual samples. A few surveys maintained the impact of genetic deviation on the accuracy of antiemetics [12-14] A few surveys build a linkage for C1236T polymorphism and clinical results. [5,12,15-17] despite of others which are unable to perform this [7,18].

Variation in outcomes between surveys contributed a lot towards phenotypic explanation, tiny sample and connectivity in substrate particularly among P-gp and various medicine efflux exchangers.[19] It was observed that reaction to ondansetron for PONV may vary substantially depending on genotypes at 2 hours after operation. It was noted that TT genotype at 1236 was linked with effective medicine reaction at 2 hours after the surgery. Chances are there that the victims having 1236TT genotype show greater handiness towards ondansetron in Central Nervous System hence showing good results towards ondansetron, leading to

lowered action of ABCB1 exchanger. It was also monitored that victims having GG genotype showed greater symptoms of PONV, leading to the point that it will probably act as interpreter of low retort towards the substrate of P-gp. So, it is evident to predict that genetic deviation of the exchanger can effect the accuracy of ondansetron. It was observed that the reaction of ondansetron towards PONV would not be altered substantially depending on genotypes at 2-24 hours after operation.

PONV is regarded as a complex issue. Various trouble causing aspects were presented among which very less showed clarity. Gender, victim's record regarding PONV or motion illness, non-smoking record, volatile anesthesia, nitrous oxide, and opioids revealed self-regulating analysts for PONV among different areas.[20] The complex genesis of PONV now-a-days is considered a serious reason of predicted treatment disappointment. PONV is influenced by a lot of aspects. None of the substantial variation was noted among risky aspects in relation to the genotypes. Various other aspects influencing PONV includes anesthetic agent and form of operation that was measured in this survey to lower the rate of alteration of the outcomes.

In Pakistan it was observed that the individual's reaction to ondansetron regarding PONV was substantially affected by ABCB1 gene and C1236T polymorphism. Sensitivity towards ondansetron act as a clinical analyst for ABCB1 genotypes in different

areas around World. For population treatment, genotyping of ABCB1 gene polymorphism (C12367T), comprising of TT, CT,CC genes play a vital role with main focus on genetic structure and antiemetic treatment through advancement of detection of the non-responders.

In Pakistan, individuals after surgery were monitored in this survey by assessing the effects of ABCB1 genetic modifications towards antiemetic effectiveness. The polymorphism of this type was not observed on a large scale before. This also build the idea of application of effective utilization of ondansetron by showing a function of ABCB1 polymorphism C1236T for therapeutically applied results. Moreover, for application of genetic examination regularly for clinical expertise, more endorsement is needed. It is recommended to perform analysis on function of polymorphisms including proteins which donate their fragment in exchange of medicine for solution of medical avoidance.

CONCLUSION:

Among a total of 426 victims, 201(47%) showed resistance against nausea or vomiting, while 225(52.8%) were affected by the disease. Evidence of nausea and vomiting after 2 hours from surgery were rare in victims having relation with 1236TT as compared to 1236(probability <0.001). Victims of CC inheritance showed huge evidence as compared to others i.e. $p < 0.001$. ABCB1 gene polymorphism act as a better predictor to forecast the reaction for ondansetron, while genetics provide basis for maintenance of PONV regarding P-gp substrates.

REFERENCES:

1. Gan, T.J. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonistic-based pharmacotherapy. *CNS Drugs*.2007;21:813-33.
2. Smith HS, Cox LR, Smith EJ. 5-HT3 receptor antagonists for the treatment of nausea/vomiting. *Ann Palliat Med*. 2012;1:115-20.
3. Belle DJ, Singh H. Genetic factors in drug metabolism. *AM. Fam. Physician*. 2008;77:1553-560.
4. Choi EM, Lee MG, Lee SH, Choi KW, Choi SH. Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting. *Anaesthesia*. 2010;65:996-1000.
5. Zimprich F1, Sunder-Plassmann R, Stogmann E, Gleiss A, DalBianco A, Zimprich A, et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. *Neurology*. 2004;63:1087-9.

6. Kwan P, Baum L, Wong V, Ng PW, Lui CH, Sin NC, et al. Association between ABCB1 C3435T polymorphism and drug-resistance epilepsy in Han Chinese. *EpilepsyBehav*.2007;11:112-7.
7. Lakhan R, Misra UK, Kalita J, Pardhan S, Gogtay NJ, Singh MK et al. No association of ABCB1 polymorphisms with drugrefactory epilepsy in a north Indian population. *Epilepsy Behav*. 2009; 14: 78-82.
8. Kim DW, lee SK, Chu K, Jang IJ, Yu KS, Cho JY et al. Lack of association between ABCB1, ABCG2 and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. *Epilepsy Res*. 2009; 84:86-90.
9. Loscher W, Delanty N. MDRI/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. *Pharmacogenetics*.2009; 10: 711-3.
10. Sambrook J, Fritich EF, Maniatis T. Molecular cloning: A laboratory Manual, 2nd ed. New York, USA: Cold Spring Harbor Laboratory Press, 1989.
11. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clin-ical relevance. *ClinPharmacolTher*. 2005;78:619-26.
12. Babaoglu MO, Bayar B, Aynacioglu AS, Kerb R, Abali H, Celik I, et al. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. *ClinPharmacolTher*. 2005;78:619-26.
13. Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch WH, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of odansetron prophylaxis? *Anesthesiology*. 2005;102:543-9.
14. Ho K, Gan T. Pharmacology, pharmacogenetics, and clinical efficacy of 5HT3 receptor antagonists for postoperative nausea and vomiting. *CurrOpinAnaesthesiol*. 2006;19:606-11.
15. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. *Pharmacogenomics*. 2005;6: 411-7.
16. Seo T, Ishitsu T, Ueda N, Nakda N, Yurube K, Ueda K et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. *Pharmacogenomics*.2006;7:551-61.
17. Maleki M1, Sayyah M, Kamgarpour F, Karimipoor M, Arab A, Rajabi A, et al. Association between ABCB1-T1236C

- Polymorphism and Drug-Resistant Epilepsy in Iranian Female Patients. *Iran Biomed J.* 2010;14:89-96.
18. Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH, Park KW, et al. Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics. *Seizure.* 2006;15:67-72.
 19. Loscher W, Delanty N. MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. *Pharmacogenomics.* 2009;10:711-13.
 20. Gan TJ. Risk factors for postoperative nausea and vomiting. *AnesthAnalg.* 2006;102:1884-98.